The Homeland Investment Act will allow Big Pharma to bring into the US a huge horde of foreign earnings at very attractive tax rates. Given the pipeline drought, some of that money is going to go to biotechs.
In the short term, Big Pharma will not lack for cash to fund their dealmaking, despite what analysts expect to be generally poor sales figures in the next year or so. One key reason: the Homeland Investment Act, passed by both houses of Congress and likely to get a signature from re-elected President Bush.
Today, to bring unremitted earnings or simple cash back into the US, companies have to pay the difference between often...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
